Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Aug 28, 2015 at 10:25 AM EDT

How Amgen Can Disrupt the Market for Cholesterol Drugs

Amgen has the potential to disrupt the market for cholesterol drugs with the newest addition to its drug portfolio.

Chris Lange | Aug 26, 2015 at 10:20 AM EDT

Acelity Files for Initial Public Offering

Acelity Holdings has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).

Chris Lange | Aug 26, 2015 at 8:55 AM EDT

Short Sellers Become More Focused in Major Biotechs

The short interest data are out for the August 14 settlement date. Biotech companies are considered a riskier group of…

Chris Lange | Aug 26, 2015 at 8:05 AM EDT

Short Sellers Have Mixed Feelings on Major Pharma

The August 14 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short…

Chris Lange | Aug 25, 2015 at 1:55 PM EDT

Mylan Fires Back at Perrigo

Mylan announced Tuesday, in conjunction with the Irish Takeover Panel, that Perrigo had made misleading statements to shareholders.

Chris Lange | Aug 25, 2015 at 11:15 AM EDT

Nabriva Files for IPO

Nabriva Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).

Jon C. Ogg | Aug 24, 2015 at 5:40 PM EDT

Mirna Therapeutics Files for IPO

Mirna Therapeutics has filed with the Securities and Exchange Commission (SEC) to conduct an initial public offering (IPO).

Jon C. Ogg | Aug 24, 2015 at 4:12 PM EDT

2 Positive Health Care REIT Views

Physicians Realty Trust and Health Care REIT were both given positive analyst views by the analyst team at Canaccord Genuity.

Chris Lange | Aug 24, 2015 at 3:58 PM EDT

Epizyme Beats Out the Market With FDA Approval

Epizyme survived the market carnage of Monday morning’s trading session. In fact this biopharma came out of the fray better…

Chris Lange | Aug 24, 2015 at 3:21 PM EDT

HMS Runs on State of New York Contract

ThinkstockHMS Holdings Corp. (NASDAQ: HMSY) is winning in the market Monday despite all the turmoil and volatility that tanked the…

Jon C. Ogg | Aug 24, 2015 at 3:04 PM EDT

FDA Grants Expanded Use of Promacta for Novartis

ThinkstockNovartis AG (NYSE: NVS) is one of the few companies with good news on a major market sell-off. Unfortunately, it…

Jon C. Ogg | Aug 24, 2015 at 2:53 PM EDT

How Relevant is Vital Therapies After Its Selloff?

ThinkstockVital Therapies Inc. (NASDAQ: VTL) was last seen trading down 80% at $3.41 (versus $17.68 close) after it said that…

Jon C. Ogg | Aug 24, 2015 at 2:09 PM EDT

Pfizer Gets Approval For Hospira Acquisition

ThinkstockAt a time when there is pressure on how large US companies are making domestic or overseas acquisitions are coming…

Chris Lange | Aug 22, 2015 at 9:40 AM EDT

What Lit a Fire Under These 3 Pharma Stocks

Over the past week, a few pharmaceutical companies made absolutely massive runs.

Chris Lange | Aug 21, 2015 at 9:40 AM EDT

Medequities Realty Trust Files for IPO

Medequities Realty Trust has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering.

1 … 248 249 250 251 252 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

How Amgen Can Disrupt the Market for Cholesterol Drugs

Acelity Files for Initial Public Offering

Short Sellers Become More Focused in Major Biotechs

Short Sellers Have Mixed Feelings on Major Pharma

Mylan Fires Back at Perrigo

Nabriva Files for IPO

Mirna Therapeutics Files for IPO

2 Positive Health Care REIT Views

Epizyme Beats Out the Market With FDA Approval

HMS Runs on State of New York Contract

FDA Grants Expanded Use of Promacta for Novartis

How Relevant is Vital Therapies After Its Selloff?

Pfizer Gets Approval For Hospira Acquisition

What Lit a Fire Under These 3 Pharma Stocks

Medequities Realty Trust Files for IPO

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Health and Healthcare Articles

All Health and Healthcare Articles

How Amgen Can Disrupt the Market for Cholesterol Drugs

Acelity Files for Initial Public Offering

Short Sellers Become More Focused in Major Biotechs

Short Sellers Have Mixed Feelings on Major Pharma

Mylan Fires Back at Perrigo

Nabriva Files for IPO

Mirna Therapeutics Files for IPO

2 Positive Health Care REIT Views

Epizyme Beats Out the Market With FDA Approval

HMS Runs on State of New York Contract

FDA Grants Expanded Use of Promacta for Novartis

How Relevant is Vital Therapies After Its Selloff?

Pfizer Gets Approval For Hospira Acquisition

What Lit a Fire Under These 3 Pharma Stocks

Medequities Realty Trust Files for IPO

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how